Table 2.
Complete group (n = 182) | Cross-validation | ||||||
---|---|---|---|---|---|---|---|
p Value | BH-corrected p value |
Significant results (p < 0.05) | Median p values | ||||
Both sets | One set | Neither set | Set 1 | Set 2 | |||
Disease parameters | |||||||
Disease duration | 0.061 | 0.25 | 0 | 371 | 629 | 0.18 | 0.20 |
DAS28 | 0.18 | 0.41 | 0 | 199 | 801 | 0.38 | 0.32 |
TJC28 | 0.10 | 0.36 | 0 | 264 | 736 | 0.25 | 0.25 |
SJC28 | 0.61 | 0.76 | 1 | 39 | 960 | 0.53 | 0.59 |
VAS | 0.21 | 0.44 | 0 | 122 | 878 | 0.39 | 0.35 |
Erosions | 0.41 | 0.60 | 0 | 61 | 939 | 0.50 | 0.51 |
Nodules | 0.24 | 0.46 | 1 | 143 | 856 | 0.39 | 0.41 |
Laboratory parameters | |||||||
ESR | 0.86 | 0.98 | 6 | 18 | 976 | 0.60 | 0.58 |
ESR dichotomous (>20) | 0.71 | 0.85 | 0 | 19 | 981 | 0.60 | 0.58 |
CRP | 0.14 | 0.39 | 0 | 233 | 767 | 0.30 | 0.29 |
CRP dichotomous (≥10) | 0.15 | 0.38 | 0 | 190 | 810 | 0.30 | 0.33 |
RF titer | 0.36 | 0.60 | 1 | 66 | 933 | 0.46 | 0.50 |
RF positivity | 0.96 | 1.0 | 3 | 3 | 994 | 0.62 | 0.61 |
ACPA titer | 0.38 | 0.59 | 0 | 64 | 936 | 0.47 | 0.51 |
ACPA positivity | 0.86 | 0.98 | 1 | 9 | 990 | 0.64 | 0.64 |
ACPA high positivity (≥3× cutoff) | 0.29 | 0.52 | 0 | 79 | 921 | 0.44 | 0.44 |
RF- and ACPA-positive vs. rest | 0.57 | 0.79 | 0 | 34 | 966 | 0.59 | 0.58 |
RF- and ACPA-negative vs. rest | 0.13 | 0.41 | 0 | 219 | 781 | 0.27 | 0.28 |
Medication parameters | |||||||
MTX use | 2 | 3 | 995 | 0.66 | 0.65 | ||
MTX dosage | 0.57 | 0.79 | 1 | 29 | 970 | 0.58 | 0.58 |
Prednisone use | 0.037 | 0.19 | 0 | 526 | 474 | 0.14 | 0.14 |
Prednisone dosage | 0.017 | 0.14 | 0 | 718 | 282 | 0.092 | 0.090 |
HCQ use | 0.001 | 0.013 | 521 | 479 | 0 | 0.015 | 0.015 |
SSZ use | 0.023 | 0.14 | 0 | 584 | 416 | 0.11 | 0.11 |
PREDN and/or HCQ and/or SSZ use | 0.00032 | 0.0080 | 612 | 388 | 0 | 0.012 | 0.010 |
Abbreviations: BH Benjamini-Hochberg, HCQ Hydroxychloroquine, SSZ Sulfasalazine, PREDN Prednisone, ACPA Anti-citrullinated protein antibodies, CRP C-reactive protein, DAS28 28-joint Disease Activity Score, DMARD Disease-modifying antirheumatic drug, ESR Erythrocyte sedimentation rate, RF Rheumatoid factor, MTX Methotrexate, SJC28 Swollen joint count in 28 joints, TJC28 Tender joint count in 28 joints, VAS Visual analogue scale